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Abstract
Sepsis is the clinical syndrome derived from the host
response to an infection and severe sepsis is the
leading cause of death in critically ill patients. Several
biomarkers have been tested for use in diagnosis and
prognostication in patients with sepsis. Soluble
urokinase-type plasminogen activator receptor (suPAR)
levels are increased in various infectious diseases, in
the blood and also in other tissues. However, the
diagnostic value of suPAR in sepsis has not been well
defined, especially compared to other more
established biomarkers, such as C-reactive protein
(CRP) and procalcitonin (PCT). On the other hand,
suPAR levels have been shown to predict outcome in
various kinds of bacteremia and recent data suggest
they may have predictive value, similar to that of
severity scores, in critically ill patients. This narrative
review provides a descriptive overview of the clinical
value of this biomarker in the diagnosis, prognosis
and therapeutic guidance of sepsis.
Keywords: infection, sepsis, biomarker, disease sever-
ity, case fatality, outcome, soluble urokinase-type plas-
minogen activator receptor, suPAR
Introduction
Sepsis is defined as the clinical syndrome resulting from
the presence of both infection and a systemic inflamma-
tory response [1]. Sepsis involves the activation of inflam-
matory and anti-inflammatory mediators, cellular and
humoral reactions, and micro- and macro-circulatory
alterations. Despite improvements in the management of
critically ill patients with serious infections, sepsis is still
the leading cause of death in critically ill patients [2].
Early diagnosis of sepsis is vital because rapid, appropri-
ate therapy is associated with improved outcomes [3].
There is, therefore, a need for better techniques to facili-
tate the diagnosis of sepsis and to monitor its course.
Various biomarkers, biological molecules that are charac-
teristic of normal or pathogenic processes and can be
easily and objectively measured, have been proposed as
being of potential use for sepsis diagnosis, therapeutic
guidance, and/or prognostication [4,5], although their
exact role remains undefined [3]. The two biomarkers
that have been most widely studied and used in patients
with sepsis are C-reactive protein (CRP) and procalcito-
nin (PCT). Levels of both these biomarkers have been
demonstrated to be raised in patients with sepsis making
them useful diagnostic indicators [6,7]. Importantly,
because they lack specificity for sepsis and levels may be
raised in other inflammatory diseases, these biomarkers
are more useful for ruling out sepsis than for ruling it in,
that is, a completely normal value makes a diagnosis of
sepsis very unlikely. PCT, in particular, has also been
used for therapeutic guidance in patients with various
types of infection [7].
Recently, the soluble form of the urokinase-type plas-
minogen activator receptor (suPAR) has attracted scienti-
fic interest because it seems to discriminate better than
some other biomarkers among patients with different
severities of illness [8]. In this narrative review, we dis-
cuss the available literature on suPAR in sepsis and pro-
vide a descriptive overview of the clinical value of this
biomarker in the diagnosis, prognosis and therapeutic
guidance of sepsis.
Structure and history of suPAR
The urokinase-type plasminogen activator (uPA) system
consists of a protease, a receptor (uPAR) and inhibitors.
In 1990, uPAR was cloned [9] and, in 1991, Ploug et al.
identified its soluble form (suPAR) [10]. uPAR is
expressed on various cell types including neutrophils,
lymphocytes, monocytes/macrophages, endothelial and
tumor cells. After cleavage from the cell surface, suPAR
can be found in the blood and other organic fluids in all
individuals, existing in three forms (I-III, II-III and I) that
have different properties related to their structural differ-
ences (Figure 1) [11]. suPAR takes part in various immu-
nological functions, including cell adhesion, migration,
chemotaxis, proteolysis, immune activation, tissue remo-
deling, invasion and signal transduction [12]. Serum
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circadian changes and are not influenced by fasting. Cer-
ebrospinal fluid (CSF), urine and serum (after centrifuga-
tion of whole blood) levels can be measured with a
monoclonal antibody double sandwich enzyme-linked
immunosorbent assay (ELISA) using commercial kits (for
example, R &D Systems, Minneapolis, MN; suPARnos-
tic™, Virogates, Copenhagen, Denmark). In healthy
adults, the median value of suPAR has been cited as 1.5
ng/ml (range: 1.2 to 1.9 ng/ml, N = 44) [13], or 2.6 ng/ml
(range: 1.5 to 4.0 ng/ml, N = 31) [14].
suPAR as a diagnostic marker of sepsis
As early as 1995, elevated plasma suPAR levels were
reported in a small group of septic intensive care unit
(ICU) patients [15]. During endotoxemia, suPAR expres-
sion is increased on peripheral blood mononuclear cells
[16] as on monocytes and granulocytes [17,18]. However,
although suPAR serum concentrations were increased
after administration of high-dose endotoxin [16], low-dose
endotoxin did not significant l yi n c r e a s ep l a s m as u P A R
levels in vivo [16]. On the other hand, PCT and CRP are
strongly induced by endotoxin [19-21], which may explain
their enhanced usefulness for the diagnosis of bacterial
infection.
In 100 patients with Crimean-Congo hemorrhagic fever
(CCHF) [22], serum suPAR levels were significantly higher
in patients with infection than in healthy controls; the
optimum diagnostic cut-off value was 3.06 ng/ml, with an
area under the receiver operating characteristic curve
(AUROC) of 0.94. In a cohort of 156 patients with sus-
pected sepsis [23], 96 of whom had bacterial infection,
AUROCs for diagnosis of bacterial sepsis were 0.72 for
PCT, 0.81 for CRP and only 0.50 for suPAR levels, sug-
gesting that suPAR was of less value for diagnosis than
these other biomarkers.
suPAR levels may be measured in other milieu than
blood. In 183 patients clinically suspected of having
meningitis, suPAR levels were significantly higher in the
CSF of patients with proven central nervous system (CNS)
infection than in those without [24]. There were no differ-
ences in CSF suPAR levels between patients with meningi-
tis and those with encephalitis but levels were significantly
higher in patients with purulent (especially in pneumococ-
cal infection) than in those with lymphocytic meningitis. A
cut-off value of 1.50 mcg/l distinguished purulent from
cleavage 
Cleavage sites 
Cleavage sites 
Figure 1 Schematic of the structure of uPAR, the mechanism of cleavage and the formation of suPAR. DI, DII, DIII represent the three
homologous domains of suPAR.
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ler study of just 12 patients with bacterial meningitis [25].
Nevertheless, because of the relatively low diagnostic sen-
sitivity and specificity, the routine use of CSF suPAR mea-
surement in CNS disease cannot be recommended at the
present time.
A study by Koch et al. [26] is currently the only pub-
lished report evaluating the diagnostic and prognostic
impact of suPAR in a large cohort of critically ill patients
(n = 273). Critically ill patients had higher serum suPAR
concentrations at admission than healthy controls. The
AUROC for prediction of sepsis was 0.62, compared to
0.86 for CRP and 0.78 for PCT. suPAR concentrations
were closely related to other sepsis markers, including
CRP, PCT, and tumor necrosis factor a levels. suPAR
levels were also inversely related to renal function (as
assessed by cystatin C, creatinine or urea levels), reflecting
the renal clearance of suPAR; they were inversely related
to albumin, and directly related to markers of cholestasis
(for example, bilirubin, alkaline phosphatase). In an
ongoing study in critically ill patients [27], we have found
that a cut-off value of 5.5 ng/ml has a sensitivity of 75%
and specificity of 72% for diagnosing sepsis. In this study,
suPAR levels were correlated to CRP levels in the whole
study population, but not in the group of patients with
sepsis.
Table 1 summarizes the available data on the diagnos-
tic value of suPAR in sepsis. Taking all these results
into consideration, it appears that suPAR has poor accu-
racy in diagnosing sepsis compared to CRP and PCT,
making suPAR of limited value as a diagnostic marker
of sepsis.
suPAR as a prognostic biomarker in sepsis
Biomarkers are relevant in clinical practice not only for
their ability to diagnose a pathological condition, but also
for predicting morbidity and outcome. Several studies
have indicated that suPAR concentrations may reflect the
severity of infection and have reported that they are asso-
ciated with a worse outcome in a range of non-infectious
and infectious diseases (Table 2). An association with
mortality has been reported in patients with malaria [28],
tuberculosis [29], and human immunodeficiency virus
(HIV) infection [30-32]. In a study of 314 HIV-1 infected
patients, the median serum suPAR value was 3.69 ng/ml
[33]. Serum levels were higher in patients with lower
CD4 counts, higher viral loads, and a higher incidence of
AIDS-related death. There was a weak but significant
negative correlation between suPAR levels and CD4
count, and a weak positive correlation between suPAR
levels and viral load. The survival curves were signifi-
cantly different for patients with low, medium and high
suPAR levels, showing lower survival rates as suPAR
levels increased. In a multivariate Cox regression model,
suPAR levels were a stronger predictor of survival than
CD4 count and viral load [33].
In a small series of patients with CCHF, serum suPAR
levels were related to renal and hepatic function and were
of prognostic value [22]. No analysis for confounding fac-
tors was made by the authors of this study, but recently,
using linear regression analysis, Koch et al.[ 2 6 ]s h o w e d
that renal and liver function were independent predictors
of elevated suPAR levels. CSF suPAR levels in patients
with meningitis were positively correlated with age, CSF
leukocyte and neutrophil count, CSF/blood-glucose ratio,
altered Glasgow Coma Scale score, and need for assisted
ventilation [24]. CSF suPAR levels were also higher in
non-survivors compared to survivors.
Kofoed et al. [34] compared the prognostic value of
suPAR to that of other biomarkers (soluble triggering
receptor expressed on myeloid cells (sTREM-1) and
macrophage migration inhibitory factor (MIF)) and of the
Simplified Acute Physiology Score (SAPS) II and Sequen-
tial Organ Failure Assessment (SOFA). Of 151 patients
with possible sepsis, 64% had a bacterial infection. suPAR
levels (measured using the suPARnostic assay, cut-off
value > 6.61 mcg/L) had a better prognostic value than
PCT and CRP, equal to that of the admission SOFA score
and almost as good as the SAPS II score; the combination
of suPAR and age had a better prognostic value than the
SAPS II score alone.
In a multicenter prospective study of 141 adult patients
with Streptococcus pneumoniae bacteremia, Wittenhagen
and colleagues [14] found that suPAR levels at admission
were significantly increased compared to those of healthy
controls. suPAR levels were higher in the 17% of patients
w h od i e df r o mt h ei n f e c t i o nt h a ni nt h o s ew h os u r v i v e d .
In a logistic multivariate regression analysis including clin-
ical variables with a prognostic value (hypotension, renal
failure, cerebral symptoms at admission, alcohol abuse),
only suPAR levels above 10 ng/ml independently predicted
mortality. The very high suPAR levels were similar to
those found in patients with Gram-negative urosepsis [35]
and in patients with bacterial meningitis [25].
Huttunen and colleagues [8] investigated suPAR levels
a sap r e d i c t o ro fd i s e a s es e v e r i t ya n dm o r t a l i t yi n1 3 2
patients with bacteremia caused by Staphylococcus aureus,
Streptococcus (pneumonia and b-hemolytic) or Escherichia
coli. The best mortality predictive cut-off level was 11 ng/
ml. During the 30-day follow-up period, 18 patients died;
15 of them had suPAR levels above 11 ng/ml, compared
to only three with levels below 11 ng/ml. Levels above this
cut-off were also associated with disease severity (hypoten-
sion, need for vasopressors or mechanical ventilation,
SOFA score ≥ 4). Logistic regression analysis gave an odds
ratio for mortality of 16.1 (95% confidence interval [CI]
4.3 to 59.9), which remained significant after adjustment
for potential confounders (for example, liver disease and
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Page 3 of 9Table 1 Studies evaluating the diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) levels
First author,
publication
date [ref]
Type Pathology Patients Period Main results Comments
Kofoed, 2007
[23]
Prospective Suspected
sepsis
156 adult, samples taken at
ED admission
12 months AUC bacterial sepsis:
suPAR 0.5, PCT 0.72
CRP 0.81
Yilmaz, 2010 [22] Retrospective CCHF 100 infected adult pts vs
volunteers.
Samples taken at hospital
admission
2006-2009
38 months
Patients (6.2 ± 4.2 ng/ml) versus controls (2.3 ± 0.6 ng/ml), P
< 0.0001. Cut-off 3.06 ng/ml
AUC 0.94 (PPV 95%, specificity 92%)
No other infections studied
Østergaard, 2004
[24]
Prospective CNS infection 183 adults, samples taken at
admission
1988 to 2002 Higher CSF levels in infected patients and in patients with
purulent meningitis versus those with lymphocytic
meningitis (P < 0.001)
Low sensitivity and specificity (69%
and 71%) with cut-off value of 1.50
mcg/l
Koch, 2011 [26] Prospective Critical illness
medical ICU
273 adults, 197 septic
patients, samples taken at
ICU admission
Undefined AUC sepsis suPAR 0.615 PCT 0.857 CRP 0.780 Correlation with renal and hepatic
function
Donadello, 2011
[27]
Prospective Critical illness
medico-surgical
ICU
152 adults, 55 septic
patients.
Samples taken at ICU
admission
December
2010 to
March 2011
AUC sepsis 0.75 (95% CI 0.66 to 0.83); correlation with CRP in
global population (r = 0.48), not in septic patients (r = 0.18)
Preliminary data
AUC, area under the curve; CCHF. Crimean Congo Hemorrhagic Fever; CNS,central nervous system; CRP, C- reactive protein; CSF, cerebrospinal fluid; ED, emergency department; PCT; procalcitonin; PPV, positive
predictive value.
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9Table 2 Studies evaluating the prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) levels
First author Type Pathology Patients Period Main results Comments
Sidenius,
2000 [33]
Retrospective HIV 314 adults, samples taken at
enrollment
1991 to
1992
Range of suPAR levels 1.15 to 15.60 ng/ml.
Low (< 3.28 ng/ml), medium (3.28-4.19 ng/ml) and
high (> 4.19 ng/ml) suPAR levels related to increasing
risk of AIDS-related death. Hazard ratio for death was
2.2 for medium suPAR levels (vs low) and 4.7 for high
suPAR levels
Samples were not all obtained at
enrollment
Eugen-Olsen,
2002 [29]
Retrospective Mycobacterium
tuberculosis
262 adults, samples taken at
enrollment in a cohort based on
suspicion of active tuberculosis
8 month-follow-up for 101 patients
1996
to1998
Elevated levels in active TB. 1.25 increase in mortality
per ng increase in suPAR.
Not all patients were followed-up
Ostrowski,
2005 [30]
Prospective HIV 59 healthy individuals + 99 HIV
patients. Samples taken at study
inclusion-median time from first
positive HIV antibody test was 8 (5 to
9) years
2000 to
2001
Higher levels predicted increased mortality risk.
suPAR(I-III) and (II-III) are independent predictors of
mortality
Measurement of suPAR (I-III),(II-III) and
(I) forms
Ostrowski,
2005 [28]
Prospective Malaria 645 African children with clinical
symptoms of malaria: 478 had
malaria.14 healthy children as controls.
Samples taken at hospital admission.
June to
August of
2000 and
2001
Highest concentrations in non-survivors (11) or with
complicated malaria. 1 ng/mL increase in suPAR
concentration was associated with increased mortality
(OR 1.42)
Low platelet count and hemoglobin
level, high neutrophil count were
independent predictors of high
plasma concentration of suPAR
Lawn, 2007
[32]
Prospective HIV 293 adults.
Samples taken at enrollment for
antiretroviral treatment
Sept 2002
to Feb
2005
5 month
follow-up
after
enrollment
Significantly higher suPAR levels in non survivors.
Log10 suPAR strongly associated with death
No discriminatory cut-off point to
provide clinically useful information
Yilmaz, 2010
[22]
Retrospective CCHF 100 adults, samples taken at hospital
admission
2006 to
2009
38 months
Cut-off value of 10.6 ng/ml AUC 0.97 Only 5/100 deaths
No comparison with other infections
Kofoed, 2008
[34]
Retrospective
sample
analysis
Suspected
sepsis
64% bacterial
infection
151 adults, samples taken at ED
admission
12 months Mortality:
suPAR AUROC 0.80 (sensitivity 89%, specificity 63%,
95% CI 0.69-0.92).
suPAR and age AUROC 0.92 (sensitivity 100%,
specificity 78%, 95% CI 0.86-0.97)
PCT and CRP had no prognostic value
Ostergaard,
2004 [24]
Prospective CNS infection 183 adults.
Samples taken at admission
1988 to
2002
Positive correlation of CSF suPAR levels with
prognosis; cut-off 3.1 mcg/l had OR for death of 11.9
(95% CI 1.4-106)
Multivariate analysis was not possible
due to small number of deaths
Wittenhagen,
2004 [14]
Multicenter
prospective
study
S. Pneumonia
bacteremia
141 adults. Samples taken at hospital
admission
1999 to
2001; 21
months
Higher suPAR levels in patients compared to healthy
volunteers (median 5.5, range 2.4 to 21.0 ng/ml).
Levels > 10 ng/ml independent predictor of mortality
(OR 13, specificity 95%, sensitivity 38%, NPV 88%, PPV
60%)
Logistic multivariate regression
analysis
Huttunen,
2011 [8]
Prospective
cohort study
Bacteremia 132 adults.
Samples taken at day 1 after the first
positive blood culture
June 1999
to Feb
2004
11 ng/ml AUROC 0.84 (95% CI 0.76 to 0.93, sensitivity
83%, specificity 76%).
Higher levels associated with disease severity.
OR for mortality16.1 (95%CI 4.3 to 59.9-logistic
regression analysis)
Plasma samples were not taken at
admission
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9Table 2 Studies evaluating the prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) levels (Continued)
Molkanen,
2011 [36]
Retrospective
sample
analysis
S. aureus
bacteremia
59 adults.
Samples taken on day 3, after positive
blood culture
suPAR AUROC for mortality 0.754 (95% CI 0.615 to
0.894, P = 0.003)
CRP AUROC 0.596.
Cut-off 9.25 ng/ml
Plasma samples not taken at
admission
Koch, 2011
[26]
Prospective Critical illness
medical ICU
273 adults, 197 septic.
Samples taken at ICU admission
Undefined Correlation of suPAR levels with APACHE II score (r =
0.345, P < 0.001), SOFA score (r = 0.337, P = 0.004),
SAPS II score (r = 0.271, P = 0.004) and the need for
VP and MV. Unadjusted OR for mortality 1.07 (95% CI
1.02 to 1.11)
Cut-off value for mortality 8 ng/ml (day 1) to 13 ng/
ml (day 3)
AUROC for ICU/overall survival larger
(0.68/0.64) than CRP (0.52/0.53), PCT
(0.55/0.55) and APACHE II (0.54/0.60),
smaller than SAPS2 (0.81/0.74)
Donadello,
2011 [27]
Prospective Critical illness,
medico-surgical
ICU
152 adults, 55 septic.
Samples taken at ICU admission
December
2010 to
March
2011
Cut-off value 6 ng/ml (sensitivity 63%, specificity 60%).
AUROC for mortality 0.71 (95% CI 0.60 to 0.81) in
overall population, in septic patients 0.68 (95% CI 0.47
to 0.88)
Preliminary data
AIDS: acquired immunodeficiency syndrome; APACHE II, Acute Physiology And Chronic Health Evaluation II; AUROC, area under the receiver operating characteristic curve; CCHF, Crimean Congo Hemorrhagic Fever;
CNS, central nervous system; CRP, C-reactive protein; CSF, cerebrospinal fluid; ED, emergency department; MV, mechanical ventilation; NPV, negative predictive value; PCT, Procalcitonin; PPV, positive predictive value;
OR, odds ratio; SAPS, Simplified Acute Physiology Score; SOFA, sequential organ failure assessment; TB, tuberculosis; VP, vasopressors.
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9renal failure). Interestingly, a simple suPAR measurement
predicted mortality at least as well as the SOFA score.
High suPAR levels were similarly demonstrated to predict
mortality in a small cohort of 59 patients with S. aureus
bacteremia [36]. Serum suPAR levels on day 3, after the
first positive blood culture for S. aureus,w e r eh i g h e ri n
the 19 patients who did not survive than in the 40 survi-
vors and this difference persisted for 10 days. The best
cut-off value was 9.25 ng/ml.
In the study by Koch et al. in critically ill patients [26],
suPAR levels were strongly linked to disease severity
scores, such as Acute Physiology and Chronic Health
Evaluation II (APACHE II), SOFA, and SAPS II scores,
and with the need for mechanical ventilation and vaso-
pressor support. Moreover, low suPAR levels at ICU
admission, and on days 3 and 7 were strong predictors of
ICU survival (ICU mortality = 28%); after multivariate
Cox regression analysis, suPAR levels retained a signifi-
cant prognostic value. The best cut-off values for ICU
survival were 8 ng/ml at day 1 and 13 ng/ml at day 3.
T h eA U R O Cf o rI C U / o v e r a l ls u r v i v a lw a sl a r g e rf o r
suPAR than for CRP, PCT and the APACHE II score, but
smaller than for the SAPS II score. In our study in a
mixed ICU cohort of patients we found that a cut-off
value of 6 ng/ml had 63% sensitivity and 60% specificity
for predicting ICU mortality with an AUROC of 0.71, but
t h i sw a sl e s st h a nt h a to ft h eA P A C H EI Ia n dS O F A
scores. The suPAR AUROC for ICU mortality in septic
patients was 0.68 [27].
Importantly, when interpreting the role of suPAR as a
prognostic marker from the results of these different stu-
dies, it is important to take into consideration the time of
blood sampling for suPAR measurement, as a stratification
biomarker that is robust during the first days of admission
is probably more useful than one that provides a predic-
tion later in the ICU course. In summary, high levels of
suPAR have been widely demonstrated to correlate with
morbidity and outcome, supporting its value as a prognos-
tic biomarker in various cohorts of infected patients;
moreover several studies have reported that values greater
than 10 ng/ml may be predictive of death.
suPAR for monitoring response to treatment
Another potentially important use for a sepsis biomarker
is in monitoring response to treatment. Adequate antimi-
crobial therapy is an essential aspect of management in
patients with sepsis but duration of antimicrobial therapy
is poorly defined. Prolonged and unnecessary use of anti-
biotics is associated with increased costs, adverse effects,
and development of antimicrobial resistance. Hence,
being able to follow response to therapy and guide anti-
microbial use could be of value, as has been suggested for
other biomarkers [37]. In this context, suPAR levels were
followed in HIV patients enrolled in an antiretroviral
treatment (ART) program in South Africa [32]. Plasma
suPAR levels were the strongest independent predictor of
short-term mortality risk but the results did not permit
determination of a discriminatory threshold that could be
used to triage patients. In patients with extra-pulmonary
mycobacterial infection, suPAR levels remained elevated
for more than six months during adequate anti-mycobac-
terial therapy [38], probably reflecting prolonged inflam-
matory activity in these patients. Furthermore, in a large
cohort of critically ill patients, suPAR levels remained
elevated during the first week of ICU treatment [26]. In a
cohort of young children suspected of having Plasmo-
dium falciparum malaria, levels of suPAR were decreased
significantly after seven days of effective treatment com-
pared to admission levels [39].
The available data suggest that sequential suPAR
levels may be of use in following the acute response to
treatment in patients with sepsis. However, the results
from these relatively small studies need to be further
validated in larger, multicenter trials before this
approach can be recommended. Moreover, the heteroge-
neous nature of the current studies prevents any meta-
analytic technique to derive an optimal range of values
for prognostication.
Conclusions
The studies that have evaluated suPAR levels vary in the
types of patient populations studied, the basal conditions
of the patients, and the methods used to measure
suPAR. The precise pathogenic involvement of suPAR
and of its different forms during sepsis has, therefore,
not been well defined. suPAR does not appear to be
superior to other biomarkers, like CRP and PCT, in
diagnosing sepsis. The independent predictive value of
suPAR levels for outcome is more clearly established.
suPAR levels may, therefore, be useful for triaging of
patients for ICU admission, as high suPAR levels may
indicate the need for more intense monitoring and
treatment. The monitoring of suPAR levels during ther-
apy needs further study to determine whether this bio-
marker could be of use in guiding therapeutic decisions.
Finally, taking into account the present lack of a ‘perfect’
unique biomarker, further studies are warranted to eval-
uate the usefulness of combining several of the available
biomarkers to improve their singular positive predictive
values.
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